clinical trial · NCT05386589
A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)
Merck Sharp & Dohme LLC·phase1·completed·n = 14
Hepatic ImpairmentMolnupiravir
brief summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of N-hydroxycytidine (NHC) following a single oral dose of molnupiravir in participants 18 to 75 years (inclusive) with moderate hepatic impairment and healthy matched controls.
started
Jun 14, 2022
primary completion
Dec 18, 2022
completion
Jan 5, 2023
last updated
Jan 28, 2025
official title
An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol